Q1e to mark low point amid organic decline... ...but we expect solid earnings development in subsequ...
Redeye comments on the positive results from a proof-of-concept study with the veterinary candidate ...
Redeye comments today's news about the collaboration with MedHelp Care, which operates one of the mo...
Q1e: Clean EBIT of ~SEK 37m Pulp prices move higher, demand stronger Fair value range: SEK 9-16/sh ...
Redeye leaves its comments following a few press releases from Acarix in the past few days.
Hansa Biopharma has announced a consecutive quarter with robust sales and the company has secured ad...
Tekniska förändringar hos Google Under Q1 och inledningen av Q2 har det genomförts en större uppdate...
Redeye comments on Modelon's news that the current CEO, Magnus Gäfvert, is set to step down from his...
We expect that cost increases will happen at a slower pace than revenue growth in 2024.
Q1e: We forecast ARR of DKK 297m, 13% adj. EBITDA margin Lifting '24e-'26e ARR by 3-1% and adj.
Zoomability Int AB (”Zoomability” eller ”Bolaget”) meddelade den 10 april att det tidigare kommunice...
Ascelia's confirmation yesterday that the three professional external readers has completed the imag...
Redeye leaves a comment following Alzinova’s announcement of updated in-depth analysis of data from ...
Alisa Bank announced a planned combination with fintech company PURO Finance.
Q1 report due 24 April Q1e net sales SEK 554m, EBITA SEK 78m Trading at 8x NTM EV/EBITA vs 10y avg.
Redeye provides a research update following the Q2 report published by Newbury yesterday.
Redeye notes that Neonode's CEO is leaving the company effective immediately, and therefore provides...
Q1'24 due 18 April +1.8% organic sales growth in Q1'24e EBITDA '24e-'26e up +1.
Redeye endorses today’s news that the nomination committee has proposed Jan Lundberg, Eli Lilly's an...
Redeye briefly comments on Lytix’ share issue. We pause our coverage.
